Cognition Therapeutics (NASDAQ:CGTX) Stock Quotes, Forecast and News Summary

Q: What sector and industry does Cognition Therapeutics (CGTX) operate in?

Cognition Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

Cognition Therapeutics Stock (NASDAQ: CGTX) stock price, news, charts, stock research, profile.

Open	$1.80
Close	$1.77
Volume / Avg.	88.54K / 149.72K
Day Range	1.75 - 1.89
52 Wk Range	0.90 - 2.95
Market Cap	$76.07M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	43
Short Interest	0.65%
Days to Cover	1.53

Recent News

Cognition Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying

The Dow Jones index closed lower by more than 100 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Avi Kapoor

Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Shares of Airspan Networks Holdings Inc. (NASDAQ: MIMO) shares rose sharply during Wednesday’s session after the company announced a partnership with GCT Semiconductor to develop an RF module. Airspan Networks Holdings shares surged 381% to $0.3699 on Wednesday.

Avi Kapoor

Why Intel Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

Gainers NKGen Biotech, Inc. (NASDAQ: NKGN) shares surged 60.9% to $6.08 in pre-market trading after gaining 8% on Thursday. NKGen Biotech presented Phase I clinical trial data at the 16th Annual Clinical Trials on Alzheimer's Disease Conference.

Lisa Levin

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Mar

May

Jun

Jul

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

About Cognition Therapeutics Inc

Sector

Health Care

Industry

Pharmaceuticals

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery an...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Cognition Therapeutics (CGTX) stock?

You can purchase shares of Cognition Therapeutics (NASDAQ:CGTX) through any online brokerage.

View our list of the best stock brokerages

Who are Cognition Therapeutics (CGTX) competitors?

Other companies in Cognition Therapeutics’s space includes: SCYNEXIS (NASDAQ:SCYX), CalciMedica (NASDAQ:CALC), Ocuphire Pharma (NASDAQ:OCUP), Rani Therapeutics Hldgs (NASDAQ:RANI) and Lipocine (NASDAQ:LPCN).

What is the target price for Cognition Therapeutics (CGTX) stock?

There is no analysis for Cognition Therapeutics.

What is the forecast for Cognition Therapeutics (CGTX) stock?

Cognition Therapeutics has a consensus price target of $9.57.

Current stock price for Cognition Therapeutics (CGTX)?

The stock price for Cognition Therapeutics (NASDAQ: CGTX) is $1.899 last updated July 3, 2024 at 8:47 AM EDT.

Does Cognition Therapeutics (CGTX) pay a dividend?

There are no upcoming dividends for Cognition Therapeutics.

When is Cognition Therapeutics (NASDAQ:CGTX) reporting earnings?

Cognition Therapeutics’s Q2 earnings are confirmed for Tuesday, August 6, 2024.

Is Cognition Therapeutics (CGTX) going to split?

There is no upcoming split for Cognition Therapeutics.

What sector and industry does Cognition Therapeutics (CGTX) operate in?

Cognition Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cognition Therapeutics

Cognition Therapeutics (CGTX) Forecast